A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
Active, not recruiting · NCT04315701 · Registry updated 2026-06-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-06-01 | NCT04315701 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
| University of Southern California | 216 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hoag Memorial Hospital | Newport Beach | United States | 18 |
| Los Angeles County-USC Medical Center | Los Angeles | United States | 32 |
| Northwestern University Feinberg School Of Medicine | Chicago | United States | 49 |
| University of Nebraska | Omaha | United States | 13 |
| USC / Norris Comprehensive Cancer Center | Los Angeles | United States | 249 |